Comparison of In Vitro Stereoselective Metabolism of Bupropion in Human, Monkey, Rat, and Mouse Liver Microsomes
Background and Objectives Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, ra...
Saved in:
Published in | European journal of drug metabolism and pharmacokinetics Vol. 44; no. 2; pp. 261 - 274 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
01.04.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background and Objectives
Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, rat, and mouse liver microsomes. The objective was to establish suitability and limitations for subsequent use of nonclinical species to model bupropion central nervous system (CNS) disposition in humans.
Methods
Hepatic microsomal incubations were conducted separately for the
R
- and
S
-bupropion enantiomers, and the formation of enantiomer-specific metabolites was determined using LC-MS/MS. Intrinsic formation clearance (CL
int
) of metabolites across the four species was determined from the formation rate versus substrate concentration relationship.
Results
The total clearance of
S
-bupropion was higher than that of
R
-bupropion in monkey and human liver microsomes. The contribution of hydroxybupropion to the total racemic bupropion clearance was 38%, 62%, 17%, and 96% in human, monkey, rat, and mouse, respectively. In the same species order, threohydrobupropion contributed 53%, 23%, 17%, and 3%, and erythrohydrobupropion contributed 9%, 14%, 66%, and 1.3%, respectively, to racemic bupropion clearance.
Conclusion
The results demonstrate that phase I metabolism in monkeys best approximates that observed in humans, and support the preferred use of this species to investigate possible pharmacokinetic factors that influence the CNS disposition of bupropion and contribute to its high intersubject variability. |
---|---|
AbstractList | Background and Objectives
Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, rat, and mouse liver microsomes. The objective was to establish suitability and limitations for subsequent use of nonclinical species to model bupropion central nervous system (CNS) disposition in humans.
Methods
Hepatic microsomal incubations were conducted separately for the
R
- and
S
-bupropion enantiomers, and the formation of enantiomer-specific metabolites was determined using LC-MS/MS. Intrinsic formation clearance (CL
int
) of metabolites across the four species was determined from the formation rate versus substrate concentration relationship.
Results
The total clearance of
S
-bupropion was higher than that of
R
-bupropion in monkey and human liver microsomes. The contribution of hydroxybupropion to the total racemic bupropion clearance was 38%, 62%, 17%, and 96% in human, monkey, rat, and mouse, respectively. In the same species order, threohydrobupropion contributed 53%, 23%, 17%, and 3%, and erythrohydrobupropion contributed 9%, 14%, 66%, and 1.3%, respectively, to racemic bupropion clearance.
Conclusion
The results demonstrate that phase I metabolism in monkeys best approximates that observed in humans, and support the preferred use of this species to investigate possible pharmacokinetic factors that influence the CNS disposition of bupropion and contribute to its high intersubject variability. Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, rat, and mouse liver microsomes. The objective was to establish suitability and limitations for subsequent use of nonclinical species to model bupropion central nervous system (CNS) disposition in humans. Hepatic microsomal incubations were conducted separately for the R- and S-bupropion enantiomers, and the formation of enantiomer-specific metabolites was determined using LC-MS/MS. Intrinsic formation clearance (CL ) of metabolites across the four species was determined from the formation rate versus substrate concentration relationship. The total clearance of S-bupropion was higher than that of R-bupropion in monkey and human liver microsomes. The contribution of hydroxybupropion to the total racemic bupropion clearance was 38%, 62%, 17%, and 96% in human, monkey, rat, and mouse, respectively. In the same species order, threohydrobupropion contributed 53%, 23%, 17%, and 3%, and erythrohydrobupropion contributed 9%, 14%, 66%, and 1.3%, respectively, to racemic bupropion clearance. The results demonstrate that phase I metabolism in monkeys best approximates that observed in humans, and support the preferred use of this species to investigate possible pharmacokinetic factors that influence the CNS disposition of bupropion and contribute to its high intersubject variability. Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, rat, and mouse liver microsomes. The objective was to establish suitability and limitations for subsequent use of nonclinical species to model bupropion central nervous system (CNS) disposition in humans.BACKGROUND AND OBJECTIVESBupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, rat, and mouse liver microsomes. The objective was to establish suitability and limitations for subsequent use of nonclinical species to model bupropion central nervous system (CNS) disposition in humans.Hepatic microsomal incubations were conducted separately for the R- and S-bupropion enantiomers, and the formation of enantiomer-specific metabolites was determined using LC-MS/MS. Intrinsic formation clearance (CLint) of metabolites across the four species was determined from the formation rate versus substrate concentration relationship.METHODSHepatic microsomal incubations were conducted separately for the R- and S-bupropion enantiomers, and the formation of enantiomer-specific metabolites was determined using LC-MS/MS. Intrinsic formation clearance (CLint) of metabolites across the four species was determined from the formation rate versus substrate concentration relationship.The total clearance of S-bupropion was higher than that of R-bupropion in monkey and human liver microsomes. The contribution of hydroxybupropion to the total racemic bupropion clearance was 38%, 62%, 17%, and 96% in human, monkey, rat, and mouse, respectively. In the same species order, threohydrobupropion contributed 53%, 23%, 17%, and 3%, and erythrohydrobupropion contributed 9%, 14%, 66%, and 1.3%, respectively, to racemic bupropion clearance.RESULTSThe total clearance of S-bupropion was higher than that of R-bupropion in monkey and human liver microsomes. The contribution of hydroxybupropion to the total racemic bupropion clearance was 38%, 62%, 17%, and 96% in human, monkey, rat, and mouse, respectively. In the same species order, threohydrobupropion contributed 53%, 23%, 17%, and 3%, and erythrohydrobupropion contributed 9%, 14%, 66%, and 1.3%, respectively, to racemic bupropion clearance.The results demonstrate that phase I metabolism in monkeys best approximates that observed in humans, and support the preferred use of this species to investigate possible pharmacokinetic factors that influence the CNS disposition of bupropion and contribute to its high intersubject variability.CONCLUSIONThe results demonstrate that phase I metabolism in monkeys best approximates that observed in humans, and support the preferred use of this species to investigate possible pharmacokinetic factors that influence the CNS disposition of bupropion and contribute to its high intersubject variability. |
Author | Van Stipdonk, Michael Bhattacharya, Chandrali Stratford, Robert E. Kirby, Danielle |
Author_xml | – sequence: 1 givenname: Chandrali surname: Bhattacharya fullname: Bhattacharya, Chandrali organization: Graduate School of Pharmaceutical Sciences, Duquesne University, Department of Pharmacy Practice, Purdue University – sequence: 2 givenname: Danielle surname: Kirby fullname: Kirby, Danielle organization: Department of Chemistry and Biochemistry, Duquesne University – sequence: 3 givenname: Michael surname: Van Stipdonk fullname: Van Stipdonk, Michael organization: Department of Chemistry and Biochemistry, Duquesne University – sequence: 4 givenname: Robert E. surname: Stratford fullname: Stratford, Robert E. email: robstrat@iu.edu organization: Graduate School of Pharmaceutical Sciences, Duquesne University, Indiana University School of Medicine, Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30298475$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc9r2zAUgMXIWLMsf8AuQ8ce4k6yZEs-tmFbAwmFbu1VyPbzUGdLriQX-t9PJs2lhwgegsf3Pd6Pz2hhnQWEvlJyRQkR3wNljMqMzFHQMuMf0DKnRMwZskBLwoTMRFWWF2gdwhNJj8mqKMpP6IKRvJJcFEs0bt0wam-Cs9h1eGfxo4ne4d8RPLgAPTTRvAA-QNS1600YZuxmGr0bTXKMxbfToO0GH5z9B68bfK_jBmvbpsQUAO-T7fHBNN4FN0D4gj52ug-wfvtX6OHnjz_b22x_92u3vd5nDeM8ZqKrQPJatmWuQVMA3jFRlG0lWF7WlBdCcqgktCAbyanWEhpeE2i0JC2VOVuhy2Pd1OnzBCGqwYQG-l5bSI2pnFLBqkJWJKHf3tCpHqBVozeD9q_qtKUEiCMwDxE8dKoxUcc0f_Ta9IoSNZ9EHU-iyBzpJIonk74zT8XPOfnRCYm1f8GrJzd5m5Z1RvoP7fidXg |
CitedBy_id | crossref_primary_10_1016_j_jpba_2020_113872 crossref_primary_10_1124_dmd_122_000867 crossref_primary_10_1007_s11419_021_00595_6 crossref_primary_10_2174_0113892002302675240903075500 crossref_primary_10_3390_genes11070729 crossref_primary_10_1007_s13318_023_00817_9 crossref_primary_10_1080_03602532_2019_1620763 crossref_primary_10_1021_acs_jafc_4c00969 |
Cites_doi | 10.1124/jpet.110.166850 10.1124/mol.104.001313 10.1002/mds.21425 10.1097/FBP.0b013e328345ca37 10.1124/dmd.108.023119 10.1001/archpsyc.1988.01800260055007 10.1093/ntr/nts088 10.1124/dmd.115.063107 10.1056/NEJMp1212969 10.1124/dmd.115.068932 10.1097/00008571-200404000-00002 10.1080/03602532.2016.1221960 10.1124/dmd.116.072363 10.4088/PCC.v07n0305 10.1124/dmd.115.068908 10.2133/dmpk.DMPK-13-RG-051 10.1016/j.bcp.2011.04.014 10.1097/00004714-199002000-00018 10.1124/dmd.113.052936 10.1016/j.biopsych.2004.12.007 10.1002/bdd.2046 10.1016/j.vascn.2014.12.005 10.1002/9781118286067 10.1124/dmd.111.043554 10.1186/1744-859X-7-19 10.1124/jpet.116.232876 10.1038/clpt.1985.228 10.1007/s11095-008-9535-1 10.4088/JCP.v59n0705 10.1081/DMR-120034149 10.4088/PCC.v04n0110a 10.1177/0091270008314254 10.1097/FPC.0b013e32835d9ab0 10.1055/s-2007-1014505 10.1038/sj.tpj.6500281 10.1016/j.brainres.2010.06.035 10.3109/00498258709043939 10.1208/s12248-017-0102-8 10.1016/S0028-3908(03)00136-9 10.4088/PCC.v06n0403 10.1016/j.tips.2011.08.005 10.1038/npp.2010.202 10.1097/00004583-200208000-00009 10.2165/00002018-200831110-00006 10.1038/npp.2008.110 10.1016/S0014-2999(03)02010-7 10.1124/dmd.114.060285 10.1002/syn.10242 10.1371/journal.pone.0002337 10.1037/a0022432 10.1007/978-3-211-45295-0_26 10.1038/clpt.2012.186 10.1016/B978-0-12-420118-7.00005-6 10.1097/01213011-200512000-00006 10.1016/S0006-3223(02)01664-5 10.1097/FBP.0000000000000224 10.1016/j.jchromb.2016.02.018 |
ContentType | Journal Article |
Copyright | Springer Nature Switzerland AG 2018 |
Copyright_xml | – notice: Springer Nature Switzerland AG 2018 |
DBID | AAYXX CITATION NPM 7X8 |
DOI | 10.1007/s13318-018-0516-4 |
DatabaseName | CrossRef PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 2107-0180 |
EndPage | 274 |
ExternalDocumentID | 30298475 10_1007_s13318_018_0516_4 |
Genre | Journal Article |
GroupedDBID | --- -EM 06D 0R~ 0VY 1N0 2JN 2KG 30V 4.4 406 408 40D 5GY 67N 96X AABHQ AACDK AAIKX AAJKR AANZL AARTL AASML AATNV AAWCG AAYIU AAYQN AAZMS ABAKF ABDZT ABFTV ABHLI ABJNI ABJOX ABKCH ABKMS ABPLI ABQBU ABTKH ABTMW ABXPI ACAOD ACCOQ ACDTI ACGFS ACKNC ACMLO ACPIV ACZOJ ADFZG ADHHG ADHIR ADINQ ADKPE ADRFC ADURQ ADZKW AEFQL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETCA AEVLU AEXYK AFBBN AFWTZ AFZKB AGAYW AGDGC AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHSBF AHYZX AIAKS AIGIU AIIXL AJRNO ALFXC ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF AMYQR ANMIH ASPBG AVWKF AWSVR AXYYD AZFZN BGNMA CSCUP DNIVK DPUIP DU5 EBLON EBS EIOEI EJD ESBYG F5P FERAY FFXSO FIGPU FLLZZ FNLPD FRRFC FSGXE GGRSB GJIRD GNWQR GQ6 GQ7 H13 HF~ HMJXF HRMNR ITM IWAJR J-C JBSCW JZLTJ KOV LLZTM M4Y NQJWS NU0 P2P R9I RLLFE ROL RSV S27 S3A S3B SBL SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPKJE SRMVM SSLCW T13 TSG U2A U9L UG4 UTJUX UZXMN VC2 VDBLX VFIZW W48 WK8 Z45 Z7U Z87 ~A9 ~JE .GJ 2.D 2VQ 53G AAAUJ AAEWM AAIAL AANXM AARHV AAYOK AAYTO AAYXX AAYZH ABBRH ABDBE ABFSG ABWHX ACBXY ACSTC ADYPR AEBTG AEKMD AEYRQ AEZWR AFDZB AFHIU AFLOW AFOHR AGJBK AHWEU AILAN AIXLP AJBLW ATHPR AYFIA BBWZM CITATION EN4 FEDTE HVGLF HZ~ O9- S1Z SBY SCLPG ABRTQ NPM 7X8 |
ID | FETCH-LOGICAL-c344t-7f9e84b8d62aea1ee4f3756d97326b145784e98ede8c841aa8ec4b0eca80d1823 |
IEDL.DBID | U2A |
ISSN | 0378-7966 2107-0180 |
IngestDate | Thu Jul 10 19:35:19 EDT 2025 Mon Jul 21 06:04:34 EDT 2025 Thu Apr 24 22:51:22 EDT 2025 Tue Jul 01 04:04:10 EDT 2025 Fri Feb 21 02:35:52 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c344t-7f9e84b8d62aea1ee4f3756d97326b145784e98ede8c841aa8ec4b0eca80d1823 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 30298475 |
PQID | 2117395890 |
PQPubID | 23479 |
PageCount | 14 |
ParticipantIDs | proquest_miscellaneous_2117395890 pubmed_primary_30298475 crossref_citationtrail_10_1007_s13318_018_0516_4 crossref_primary_10_1007_s13318_018_0516_4 springer_journals_10_1007_s13318_018_0516_4 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-04-01 |
PublicationDateYYYYMMDD | 2019-04-01 |
PublicationDate_xml | – month: 04 year: 2019 text: 2019-04-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham – name: France |
PublicationTitle | European journal of drug metabolism and pharmacokinetics |
PublicationTitleAbbrev | Eur J Drug Metab Pharmacokinet |
PublicationTitleAlternate | Eur J Drug Metab Pharmacokinet |
PublicationYear | 2019 |
Publisher | Springer International Publishing |
Publisher_xml | – name: Springer International Publishing |
References | Kielbasa, Stratford (CR53) 2012; 40 Connarn (CR15) 2017; 19 CR38 Benowitz (CR13) 2013; 23 CR32 Dalgaard (CR59) 2015; 74 Wang (CR60) 2011; 82 Schindler (CR61) 2011; 19 Sager, Price, Isoherranen (CR28) 2016; 44 Volkow (CR36) 2005; 57 Silverstone (CR29) 2008; 7 Cremers (CR48) 2016; 44 Woodcock, Khan, Yu (CR7) 2012; 367 Beyens (CR19) 2008; 31 Hansard (CR51) 2011; 22 CR2 Avdeef (CR64) 2012 Sharon, Tyndale (CR45) 2009; 34 Khokhar, Tyndale (CR43) 2011; 36 CR6 CR5 Davidson (CR17) 1990; 10 Hesse (CR10) 2004; 14 Damaj (CR26) 2010; 334 Ascher (CR37) 1995; 56 CR42 Grandas, López-Manzanares (CR16) 2007; 22 Suckow (CR24) 1986; 14 Damaj (CR25) 2004; 66 Kharasch, Mitchell, Coles (CR22) 2008; 48 Meyer (CR50) 2013; 41 Fava (CR1) 2005; 7 Deveaugh-Geiss (CR35) 2002; 41 Golden (CR8) 1988; 45 Skarydova (CR30) 2014; 29 Gufford (CR20) 2016; 44 Martin (CR39) 1990; 23 Khokhar, Miksys, Tyndale (CR47) 2010; 1348 CR12 Reimherr (CR3) 2005; 1 CR54 Miksys (CR63) 2003; 45 Connarn (CR9) 2016; 37 Ferguson, Tyndale (CR44) 2011; 32 Masters (CR21) 2016; 358 Dunner, Billow (CR55) 1998; 59 Berigan (CR4) 2002; 4 Swan (CR31) 2004; 5 Kielbasa, Kalvass, Stratford (CR52) 2009; 37 Coles, Kharasch (CR23) 2008; 25 Stahl (CR56) 2004; 6 Zhu (CR14) 2014; 42 CR27 Connarn (CR57) 2015; 43 Grabus, Carroll, Damaj (CR34) 2012; 14 Laizure (CR11) 1985; 38 Agarwal (CR40) 2008; 3 Welch, Lai, Schroeder (CR49) 1987; 17 Bondarev (CR33) 2003; 474 CR62 Johnston, Ascher (CR18) 1991; 52 Bruijnzeel, Markou (CR58) 2003; 50 Toselli, Dodd, Gillam (CR46) 2016; 48 Miksys, Tyndale (CR41) 2004; 36 DL Dunner (516_CR55) 1998; 59 LM Hesse (516_CR10) 2004; 14 SC Laizure (516_CR11) 1985; 38 V Agarwal (516_CR40) 2008; 3 P Martin (516_CR39) 1990; 23 J Woodcock (516_CR7) 2012; 367 S Miksys (516_CR41) 2004; 36 JN Connarn (516_CR57) 2015; 43 516_CR2 JN Connarn (516_CR15) 2017; 19 MJ Hansard (516_CR51) 2011; 22 SM Stahl (516_CR56) 2004; 6 AZX Zhu (516_CR14) 2014; 42 516_CR42 RM Welch (516_CR49) 1987; 17 BT Gufford (516_CR20) 2016; 44 A Avdeef (516_CR64) 2012 MI Damaj (516_CR25) 2004; 66 JY Khokhar (516_CR47) 2010; 1348 GE Swan (516_CR31) 2004; 5 JE Sager (516_CR28) 2016; 44 ND Volkow (516_CR36) 2005; 57 CS Ferguson (516_CR44) 2011; 32 RF Suckow (516_CR24) 1986; 14 516_CR38 FW Reimherr (516_CR3) 2005; 1 L Skarydova (516_CR30) 2014; 29 TIFH Cremers (516_CR48) 2016; 44 NL Benowitz (516_CR13) 2013; 23 516_CR32 A Meyer (516_CR50) 2013; 41 J Deveaugh-Geiss (516_CR35) 2002; 41 AW Bruijnzeel (516_CR58) 2003; 50 X Wang (516_CR60) 2011; 82 ED Kharasch (516_CR22) 2008; 48 S Miksys (516_CR63) 2003; 45 JY Khokhar (516_CR43) 2011; 36 M-N Beyens (516_CR19) 2008; 31 JALC Johnston (516_CR18) 1991; 52 AR Masters (516_CR21) 2016; 358 CW Schindler (516_CR61) 2011; 19 RN Golden (516_CR8) 1988; 45 PH Silverstone (516_CR29) 2008; 7 R Coles (516_CR23) 2008; 25 W Kielbasa (516_CR53) 2012; 40 516_CR27 ML Bondarev (516_CR33) 2003; 474 M Fava (516_CR1) 2005; 7 JA Ascher (516_CR37) 1995; 56 JN Connarn (516_CR9) 2016; 37 516_CR62 MI Damaj (516_CR26) 2010; 334 J Davidson (516_CR17) 1990; 10 L Dalgaard (516_CR59) 2015; 74 516_CR5 516_CR6 W Kielbasa (516_CR52) 2009; 37 M Sharon (516_CR45) 2009; 34 TR Berigan (516_CR4) 2002; 4 F Toselli (516_CR46) 2016; 48 516_CR12 SD Grabus (516_CR34) 2012; 14 F Grandas (516_CR16) 2007; 22 516_CR54 |
References_xml | – volume: 334 start-page: 1087 issue: 3 year: 2010 end-page: 1095 ident: CR26 article-title: Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice publication-title: J Pharmacol Experim Therapeut doi: 10.1124/jpet.110.166850 – volume: 66 start-page: 675 issue: 3 year: 2004 ident: CR25 article-title: Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors publication-title: Mol Pharmacol doi: 10.1124/mol.104.001313 – volume: 56 start-page: 395 issue: 9 year: 1995 end-page: 401 ident: CR37 article-title: Bupropion: a review of its mechanism of antidepressant activity publication-title: J Clin Psychiatry – volume: 22 start-page: 1830 issue: 12 year: 2007 end-page: 1831 ident: CR16 article-title: Bupropion-induced parkinsonism publication-title: Mov Disord doi: 10.1002/mds.21425 – volume: 22 start-page: 269 issue: 3 year: 2011 end-page: 274 ident: CR51 article-title: A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets publication-title: Behav Pharmacol doi: 10.1097/FBP.0b013e328345ca37 – volume: 37 start-page: 137 issue: 1 year: 2009 end-page: 142 ident: CR52 article-title: Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats publication-title: Drug Metab Dispos doi: 10.1124/dmd.108.023119 – volume: 45 start-page: 145 issue: 2 year: 1988 end-page: 149 ident: CR8 article-title: Bupropion in depression. II. The role of metabolites in clinical outcome publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1988.01800260055007 – ident: CR12 – volume: 14 start-page: 1356 issue: 11 year: 2012 end-page: 1361 ident: CR34 article-title: Bupropion and its main metabolite reverse nicotine chronic tolerance in the mouse publication-title: Nicotine Tob Res doi: 10.1093/ntr/nts088 – volume: 43 start-page: 1019 issue: 7 year: 2015 end-page: 1027 ident: CR57 article-title: Metabolism of bupropion by carbonyl reductases in liver and intestine publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.063107 – volume: 367 start-page: 2463 issue: 26 year: 2012 end-page: 2465 ident: CR7 article-title: Withdrawal of generic budeprion for nonbioequivalence publication-title: N Engl J Med doi: 10.1056/NEJMp1212969 – volume: 44 start-page: 624 issue: 5 year: 2016 end-page: 633 ident: CR48 article-title: Development of a rat plasma and brain extracellular fluid pharmacokinetic model for bupropion and hydroxybupropion based on microdialysis sampling, and application to predict human brain concentrations publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.068932 – ident: CR54 – volume: 14 start-page: 225 issue: 4 year: 2004 end-page: 238 ident: CR10 article-title: Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes publication-title: Pharmacogenet Genomics doi: 10.1097/00008571-200404000-00002 – volume: 48 start-page: 379 issue: 3 year: 2016 end-page: 404 ident: CR46 article-title: Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs publication-title: Drug Metab Rev doi: 10.1080/03602532.2016.1221960 – volume: 52 start-page: 450 year: 1991 end-page: 456 ident: CR18 article-title: A 102-center prospective study of seizure in association with bupropion publication-title: J Clin Psychiatry – volume: 44 start-page: 1709 issue: 10 year: 2016 end-page: 1719 ident: CR28 article-title: Stereoselective metabolism of bupropion to OH-bupropion, threohydrobupropion, erythrohydrobupropion, and 4′-OH-bupropion in vitro publication-title: Drug Metab Dispos doi: 10.1124/dmd.116.072363 – volume: 7 start-page: 106 issue: 3 year: 2005 end-page: 113 ident: CR1 article-title: 15 years of clinical experience with bupropion HCL: from bupropion to bupropion SR to bupropion XL publication-title: Prim Care Compan J Clin Psychiatry doi: 10.4088/PCC.v07n0305 – volume: 44 start-page: 544 issue: 4 year: 2016 end-page: 553 ident: CR20 article-title: Stereoselective glucuronidation of bupropion metabolites in vitro and in vivo publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.068908 – volume: 29 start-page: 177 issue: 2 year: 2014 end-page: 184 ident: CR30 article-title: Deeper insight into the reducing biotransformation of bupropion in the human liver publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.DMPK-13-RG-051 – ident: CR42 – volume: 82 start-page: 295 issue: 3 year: 2011 end-page: 303 ident: CR60 article-title: Metabolism of bupropion by baboon hepatic and placental microsomes publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2011.04.014 – volume: 10 start-page: 60 issue: 1 year: 1990 end-page: 62 ident: CR17 article-title: Seizures and bupropion: a review publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-199002000-00018 – volume: 1 start-page: 245 issue: 3 year: 2005 end-page: 251 ident: CR3 article-title: Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial publication-title: Neuropsychiatr Dis Treatm – volume: 41 start-page: 1671 issue: 9 year: 2013 end-page: 1678 ident: CR50 article-title: Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1 publication-title: Drug Metab Dispos doi: 10.1124/dmd.113.052936 – volume: 57 start-page: 640 issue: 6 year: 2005 end-page: 646 ident: CR36 article-title: The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects publication-title: Biol Psychiat doi: 10.1016/j.biopsych.2004.12.007 – volume: 37 start-page: 550 issue: 9 year: 2016 end-page: 560 ident: CR9 article-title: Identification of non-reported bupropion metabolites in human plasma publication-title: Biopharm Drug Dispos doi: 10.1002/bdd.2046 – volume: 74 start-page: 80 year: 2015 end-page: 92 ident: CR59 article-title: Comparison of minipig, dog, monkey and human drug metabolism and disposition publication-title: J Pharmacol Toxicol Methods doi: 10.1016/j.vascn.2014.12.005 – start-page: 595 year: 2012 ident: CR64 publication-title: Permeability: blood-brain barrier in absorption and drug development solubility, permeability, and charge state doi: 10.1002/9781118286067 – volume: 40 start-page: 877 issue: 5 year: 2012 end-page: 883 ident: CR53 article-title: Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses publication-title: Drug Metab Dispos doi: 10.1124/dmd.111.043554 – volume: 7 start-page: 19 year: 2008 ident: CR29 article-title: Convulsive liability of bupropion hydrochloride metabolites in Swiss albino mice publication-title: Ann Gen Psychiatry doi: 10.1186/1744-859X-7-19 – volume: 358 start-page: 230 issue: 2 year: 2016 end-page: 238 ident: CR21 article-title: Chiral plasma pharmacokinetics and urinary excretion of bupropion and metabolites in healthy volunteers publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.116.232876 – ident: CR32 – volume: 38 start-page: 586 issue: 5 year: 1985 end-page: 589 ident: CR11 article-title: Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1985.228 – volume: 25 start-page: 1405 issue: 6 year: 2008 end-page: 1411 ident: CR23 article-title: Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes publication-title: Pharm Res doi: 10.1007/s11095-008-9535-1 – ident: CR5 – volume: 59 start-page: 366 year: 1998 end-page: 373 ident: CR55 article-title: A prospective safety surveillance study for bupropion sustained-release in the treatment of depression publication-title: J Clin Psychiatry doi: 10.4088/JCP.v59n0705 – volume: 36 start-page: 313 issue: 2 year: 2004 end-page: 333 ident: CR41 article-title: The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics publication-title: Drug Metab Rev doi: 10.1081/DMR-120034149 – ident: CR2 – volume: 4 start-page: 30 issue: 1 year: 2002 end-page: 32 ident: CR4 article-title: The many uses of bupropion and bupropion sustained release (SR) in adults publication-title: Prim Care Compan J Clin Psychiatry doi: 10.4088/PCC.v04n0110a – volume: 48 start-page: 464 issue: 4 year: 2008 end-page: 474 ident: CR22 article-title: Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity publication-title: J Clin Pharmacol doi: 10.1177/0091270008314254 – volume: 23 start-page: 135 issue: 3 year: 2013 end-page: 141 ident: CR13 article-title: Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e32835d9ab0 – volume: 23 start-page: 187 issue: 04 year: 1990 end-page: 194 ident: CR39 article-title: Antidepressant profile of bupropion and three metabolites in mice publication-title: Pharmacopsychiatry doi: 10.1055/s-2007-1014505 – ident: CR6 – volume: 5 start-page: 21 year: 2004 ident: CR31 article-title: Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR publication-title: Pharmacogenomics J doi: 10.1038/sj.tpj.6500281 – volume: 1348 start-page: 1 year: 2010 end-page: 9 ident: CR47 article-title: Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors publication-title: Brain Res doi: 10.1016/j.brainres.2010.06.035 – ident: CR27 – volume: 17 start-page: 287 issue: 3 year: 1987 end-page: 298 ident: CR49 article-title: Pharmacological significance of the species differences in bupropion metabolism publication-title: Xenobiotica doi: 10.3109/00498258709043939 – volume: 19 start-page: 1513 issue: 5 year: 2017 end-page: 1522 ident: CR15 article-title: Pharmacokinetics and pharmacogenomics of bupropion in three different formulations with different release kinetics in healthy human volunteers publication-title: AAPS J doi: 10.1208/s12248-017-0102-8 – volume: 45 start-page: 122 issue: 1 year: 2003 end-page: 132 ident: CR63 article-title: Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain publication-title: Neuropharmacology doi: 10.1016/S0028-3908(03)00136-9 – volume: 6 start-page: 159 issue: 4 year: 2004 end-page: 166 ident: CR56 article-title: A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor publication-title: Prim Care Compan J Clin Psychiatry doi: 10.4088/PCC.v06n0403 – ident: CR38 – volume: 32 start-page: 708 issue: 12 year: 2011 end-page: 714 ident: CR44 article-title: Cytochromes P450 in the brain: emerging evidence for biological significance publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2011.08.005 – volume: 36 start-page: 692 issue: 3 year: 2011 end-page: 700 ident: CR43 article-title: Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects publication-title: Neuropsychopharmacology doi: 10.1038/npp.2010.202 – volume: 41 start-page: 914 issue: 8 year: 2002 end-page: 920 ident: CR35 article-title: GW320659 for the treatment of attention-deficit/hyperactivity disorder in children publication-title: J Am Acad Child Adolesc Psychiatry doi: 10.1097/00004583-200208000-00009 – volume: 31 start-page: 1017 issue: 11 year: 2008 end-page: 1026 ident: CR19 article-title: Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004 publication-title: Drug Saf doi: 10.2165/00002018-200831110-00006 – volume: 34 start-page: 634 issue: 3 year: 2009 end-page: 640 ident: CR45 article-title: Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition publication-title: Neuropsychopharmacology doi: 10.1038/npp.2008.110 – volume: 474 start-page: 85 issue: 1 year: 2003 end-page: 93 ident: CR33 article-title: Behavioral and biochemical investigations of bupropion metabolites publication-title: Eur J Pharmacol doi: 10.1016/S0014-2999(03)02010-7 – ident: CR62 – volume: 42 start-page: 1971 issue: 11 year: 2014 end-page: 1977 ident: CR14 article-title: Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes publication-title: Drug Metab Dispos doi: 10.1124/dmd.114.060285 – volume: 14 start-page: 692 issue: 6 year: 1986 end-page: 697 ident: CR24 article-title: Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs publication-title: Drug Metab Dispos – volume: 50 start-page: 20 issue: 1 year: 2003 end-page: 28 ident: CR58 article-title: Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats publication-title: Synapse doi: 10.1002/syn.10242 – volume: 3 start-page: e2337 issue: 6 year: 2008 ident: CR40 article-title: Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite publication-title: PLoS One doi: 10.1371/journal.pone.0002337 – volume: 19 start-page: 1 issue: 1 year: 2011 end-page: 10 ident: CR61 article-title: Comparison of the effects of methamphetamine, bupropion and methylphenidate on the self-administration of methamphetamine by rhesus monkeys publication-title: Exp Clin Psychopharmacol doi: 10.1037/a0022432 – ident: 516_CR42 doi: 10.1007/978-3-211-45295-0_26 – ident: 516_CR12 doi: 10.1038/clpt.2012.186 – volume: 23 start-page: 135 issue: 3 year: 2013 ident: 516_CR13 publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e32835d9ab0 – volume: 6 start-page: 159 issue: 4 year: 2004 ident: 516_CR56 publication-title: Prim Care Compan J Clin Psychiatry doi: 10.4088/PCC.v06n0403 – volume: 34 start-page: 634 issue: 3 year: 2009 ident: 516_CR45 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2008.110 – volume: 37 start-page: 550 issue: 9 year: 2016 ident: 516_CR9 publication-title: Biopharm Drug Dispos doi: 10.1002/bdd.2046 – volume: 29 start-page: 177 issue: 2 year: 2014 ident: 516_CR30 publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.DMPK-13-RG-051 – volume: 41 start-page: 1671 issue: 9 year: 2013 ident: 516_CR50 publication-title: Drug Metab Dispos doi: 10.1124/dmd.113.052936 – volume: 38 start-page: 586 issue: 5 year: 1985 ident: 516_CR11 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1985.228 – volume: 44 start-page: 544 issue: 4 year: 2016 ident: 516_CR20 publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.068908 – ident: 516_CR27 doi: 10.1016/B978-0-12-420118-7.00005-6 – ident: 516_CR2 – ident: 516_CR32 doi: 10.1097/01213011-200512000-00006 – volume: 37 start-page: 137 issue: 1 year: 2009 ident: 516_CR52 publication-title: Drug Metab Dispos doi: 10.1124/dmd.108.023119 – volume: 1348 start-page: 1 year: 2010 ident: 516_CR47 publication-title: Brain Res doi: 10.1016/j.brainres.2010.06.035 – volume: 19 start-page: 1513 issue: 5 year: 2017 ident: 516_CR15 publication-title: AAPS J doi: 10.1208/s12248-017-0102-8 – volume: 7 start-page: 19 year: 2008 ident: 516_CR29 publication-title: Ann Gen Psychiatry doi: 10.1186/1744-859X-7-19 – volume: 82 start-page: 295 issue: 3 year: 2011 ident: 516_CR60 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2011.04.014 – volume: 56 start-page: 395 issue: 9 year: 1995 ident: 516_CR37 publication-title: J Clin Psychiatry – volume: 66 start-page: 675 issue: 3 year: 2004 ident: 516_CR25 publication-title: Mol Pharmacol doi: 10.1124/mol.104.001313 – volume: 14 start-page: 1356 issue: 11 year: 2012 ident: 516_CR34 publication-title: Nicotine Tob Res doi: 10.1093/ntr/nts088 – volume: 7 start-page: 106 issue: 3 year: 2005 ident: 516_CR1 publication-title: Prim Care Compan J Clin Psychiatry doi: 10.4088/PCC.v07n0305 – volume: 334 start-page: 1087 issue: 3 year: 2010 ident: 516_CR26 publication-title: J Pharmacol Experim Therapeut doi: 10.1124/jpet.110.166850 – volume: 19 start-page: 1 issue: 1 year: 2011 ident: 516_CR61 publication-title: Exp Clin Psychopharmacol doi: 10.1037/a0022432 – volume: 5 start-page: 21 year: 2004 ident: 516_CR31 publication-title: Pharmacogenomics J doi: 10.1038/sj.tpj.6500281 – ident: 516_CR38 – volume: 17 start-page: 287 issue: 3 year: 1987 ident: 516_CR49 publication-title: Xenobiotica doi: 10.3109/00498258709043939 – volume: 74 start-page: 80 year: 2015 ident: 516_CR59 publication-title: J Pharmacol Toxicol Methods doi: 10.1016/j.vascn.2014.12.005 – volume: 45 start-page: 122 issue: 1 year: 2003 ident: 516_CR63 publication-title: Neuropharmacology doi: 10.1016/S0028-3908(03)00136-9 – volume: 40 start-page: 877 issue: 5 year: 2012 ident: 516_CR53 publication-title: Drug Metab Dispos doi: 10.1124/dmd.111.043554 – ident: 516_CR5 – volume: 44 start-page: 1709 issue: 10 year: 2016 ident: 516_CR28 publication-title: Drug Metab Dispos doi: 10.1124/dmd.116.072363 – volume: 22 start-page: 269 issue: 3 year: 2011 ident: 516_CR51 publication-title: Behav Pharmacol doi: 10.1097/FBP.0b013e328345ca37 – volume: 32 start-page: 708 issue: 12 year: 2011 ident: 516_CR44 publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2011.08.005 – volume: 4 start-page: 30 issue: 1 year: 2002 ident: 516_CR4 publication-title: Prim Care Compan J Clin Psychiatry doi: 10.4088/PCC.v04n0110a – volume: 1 start-page: 245 issue: 3 year: 2005 ident: 516_CR3 publication-title: Neuropsychiatr Dis Treatm – volume: 44 start-page: 624 issue: 5 year: 2016 ident: 516_CR48 publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.068932 – volume: 36 start-page: 692 issue: 3 year: 2011 ident: 516_CR43 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2010.202 – volume: 474 start-page: 85 issue: 1 year: 2003 ident: 516_CR33 publication-title: Eur J Pharmacol doi: 10.1016/S0014-2999(03)02010-7 – ident: 516_CR6 doi: 10.1016/S0006-3223(02)01664-5 – volume: 358 start-page: 230 issue: 2 year: 2016 ident: 516_CR21 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.116.232876 – volume: 57 start-page: 640 issue: 6 year: 2005 ident: 516_CR36 publication-title: Biol Psychiat doi: 10.1016/j.biopsych.2004.12.007 – volume: 48 start-page: 464 issue: 4 year: 2008 ident: 516_CR22 publication-title: J Clin Pharmacol doi: 10.1177/0091270008314254 – volume: 3 start-page: e2337 issue: 6 year: 2008 ident: 516_CR40 publication-title: PLoS One doi: 10.1371/journal.pone.0002337 – volume: 52 start-page: 450 year: 1991 ident: 516_CR18 publication-title: J Clin Psychiatry – start-page: 595 volume-title: Permeability: blood-brain barrier in absorption and drug development solubility, permeability, and charge state year: 2012 ident: 516_CR64 doi: 10.1002/9781118286067 – volume: 42 start-page: 1971 issue: 11 year: 2014 ident: 516_CR14 publication-title: Drug Metab Dispos doi: 10.1124/dmd.114.060285 – volume: 36 start-page: 313 issue: 2 year: 2004 ident: 516_CR41 publication-title: Drug Metab Rev doi: 10.1081/DMR-120034149 – volume: 22 start-page: 1830 issue: 12 year: 2007 ident: 516_CR16 publication-title: Mov Disord doi: 10.1002/mds.21425 – volume: 25 start-page: 1405 issue: 6 year: 2008 ident: 516_CR23 publication-title: Pharm Res doi: 10.1007/s11095-008-9535-1 – volume: 14 start-page: 692 issue: 6 year: 1986 ident: 516_CR24 publication-title: Drug Metab Dispos – ident: 516_CR62 doi: 10.1097/FBP.0000000000000224 – volume: 10 start-page: 60 issue: 1 year: 1990 ident: 516_CR17 publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-199002000-00018 – volume: 367 start-page: 2463 issue: 26 year: 2012 ident: 516_CR7 publication-title: N Engl J Med doi: 10.1056/NEJMp1212969 – volume: 50 start-page: 20 issue: 1 year: 2003 ident: 516_CR58 publication-title: Synapse doi: 10.1002/syn.10242 – ident: 516_CR54 doi: 10.1016/j.jchromb.2016.02.018 – volume: 31 start-page: 1017 issue: 11 year: 2008 ident: 516_CR19 publication-title: Drug Saf doi: 10.2165/00002018-200831110-00006 – volume: 23 start-page: 187 issue: 04 year: 1990 ident: 516_CR39 publication-title: Pharmacopsychiatry doi: 10.1055/s-2007-1014505 – volume: 41 start-page: 914 issue: 8 year: 2002 ident: 516_CR35 publication-title: J Am Acad Child Adolesc Psychiatry doi: 10.1097/00004583-200208000-00009 – volume: 45 start-page: 145 issue: 2 year: 1988 ident: 516_CR8 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1988.01800260055007 – volume: 43 start-page: 1019 issue: 7 year: 2015 ident: 516_CR57 publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.063107 – volume: 48 start-page: 379 issue: 3 year: 2016 ident: 516_CR46 publication-title: Drug Metab Rev doi: 10.1080/03602532.2016.1221960 – volume: 14 start-page: 225 issue: 4 year: 2004 ident: 516_CR10 publication-title: Pharmacogenet Genomics doi: 10.1097/00008571-200404000-00002 – volume: 59 start-page: 366 year: 1998 ident: 516_CR55 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v59n0705 |
SSID | ssj0000389556 |
Score | 2.1978655 |
Snippet | Background and Objectives
Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared... Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of... |
SourceID | proquest pubmed crossref springer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 261 |
SubjectTerms | Biomedical and Life Sciences Biomedicine Human Physiology Medical Biochemistry Original Research Article Pharmaceutical Sciences/Technology Pharmacology/Toxicology Pharmacy |
Title | Comparison of In Vitro Stereoselective Metabolism of Bupropion in Human, Monkey, Rat, and Mouse Liver Microsomes |
URI | https://link.springer.com/article/10.1007/s13318-018-0516-4 https://www.ncbi.nlm.nih.gov/pubmed/30298475 https://www.proquest.com/docview/2117395890 |
Volume | 44 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dT9swED-N8rIXNBjbygDdpIkHSCS3thPnsSAY-yhCQCf2FDnJVaoESUXSh_73nPPRamKbtAe_RI4T-Xz273x3vwP4LFNtMyUzn7QMfGXJ-ImIUp_EMBJJYlVgXe7w-Cq4nKhv9_q-zeMuu2j3ziVZ79TrZDfJ649NX256wONuwKZm093FcU2Go9XFimOM07rxUbKFFDKe77yZfxrl9_PoBch84SCtz52LN7DVAkYcNRLehleU78DRdcM4vfTwbp1AVXp4hNdrLurlW5ifreoMYjHFrzn-nFVPBd7ydFJR1kVweL_DMVW8Gh5m5aPrdrrgP5yzxHCWY33N7yErP-u7hze28tDmGT9YlIQ_XFwHjl1YX1k8UrkLk4vzu7NLvy2y4KdSqcoPpxEZlZgsGFqyAyI1laEOMsfiEyQDxRqtKDKUkUmNGlhrKFWJoNQakbFxIt9BLy9y-gAoHbU87_3apBGjrMRSJkKS1oopw64o7IPopjpOWwZyVwjjIV5zJzvpxMI1lk6s-nC8emXe0G_8q_OnTn4xK4nzfNiceDJitnKdQ9JEog_vG8GuhpOOhF6Fug8nnaTjVo_Lv39r7796f4TXDLSiJuJnH3rV04IOGMxUySFsjr78-n5-WC_iZ6cD7CI |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VcoAL4k14lEGCHsCWNt61vT5w6IMqoUlVQYJ6c9f2RIrU2lHtCOX38EeZ9SNRVUDi0MNerPV6td_s7Ixn5luA9zL1TaZk5pIvA1cZ0m4iotQl4UUiSYwKjK0dHp8Eg6n6euafbcGvrhamznbvQpK1pt4Uu0mWP3Z9ufl9HrfNpDym1U_208rPw0MG9YPnHX2ZHAzc9ioBN5VKVW44i0irRGeBZ8j0idRMhn6QWa6aIOkrlltFkaaMdKpV3xhNqUoEpUaLjE1wyePegbtse2i7dabe3vpHjmWo8_0mJsoeWcj-Qxc9_dOsr59_N4zaGwHZ-pw7eggPWgMV9xqJegRblD-G3dOG4Xrl4GRTsFU6uIunG-7r1RNYHKzvNcRihsMcf8yrqwK_M3xUlPWlO6xfcUwVS9_FvLy03faXPMMFSwjOc6zDCg6ysmH94uA3Uzlo8owfLEvCkc0jwbFNIyyLSyqfwvRWkHgG23mR0wtAaans-azxdRqxVZcYykRI0hgxYzMvCnsguqWO05bx3F68cRFvuJotOrGwjdGJVQ8-rl9ZNHQf_-r8rsMv5k1pIy0mJ16MmL1qGwDVkejB8wbY9XDSkt6r0O_Bpw7puNUb5d-_9fK_er-Fe4PJeBSPhifHr-A-G3lRk230GrarqyW9YUOqSnZqQUY4v-2d8xs91Chc |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIiEuiDfL00jQAySqN7YT58ChtKy6tFutoIt6C048kVZqk1WTFdpfxV9knMeuUAGJQw--RI4d-RvbM5mZbwDeiEwZK4X1UYnQlwa1n_I485EHMU9TI0PjcocnJ-HhTH4-U2db8LPPhWmi3XuXZJvT4Fiainp3YfPdTeKbIFkkM5iaGtIcXVTlEa5-kM1WfRgfEMBvg2D06XT_0O_KCviZkLL2ozxGLVNtw8CgGSLKXEQqtI63JkyHkmRYYqzRos60HBqjMZMpx8xobkkdFzTuDbgpXfIxbaBZsLf-qePY6pRq_aNknUVkS_Se1D999e934RUF94pztrnzRnfhTqessr1Wuu7BFhb3YWfasl2vPHa6Sd6qPLbDphse7NUDWOyvaxyyMmfjgn2b15cl-0pQYlk1BXjorGUTrEkSz-fVhev2cUlfuCBpYfOCNS4Gj9HBQ2eNx76Y2mOmsPRgWSE7djElbOJCCqvyAquHMLsWJB7BdlEW-ASYcLT2dO8oncWk4aUGLY9QGMNzUvniaAC8X-ok69jPXRGO82TD2-zQSbhrhE4iB_Bu_cqipf74V-fXPX4JbVDndTEF0mIkZGE7Z6iO-QAet8CuhxOOAF9GagDve6ST7gyp_j7X0__q_QpuTQ9GyfH45OgZ3CZ9L24Dj57Ddn25xBekU9Xpy0aOGXy_7o3zC2qbLI8 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+In+Vitro+Stereoselective+Metabolism+of+Bupropion+in+Human%2C+Monkey%2C+Rat%2C+and+Mouse+Liver+Microsomes&rft.jtitle=European+journal+of+drug+metabolism+and+pharmacokinetics&rft.au=Bhattacharya%2C+Chandrali&rft.au=Kirby%2C+Danielle&rft.au=Van+Stipdonk%2C+Michael&rft.au=Stratford%2C+Robert+E.&rft.date=2019-04-01&rft.pub=Springer+International+Publishing&rft.issn=0378-7966&rft.eissn=2107-0180&rft.volume=44&rft.issue=2&rft.spage=261&rft.epage=274&rft_id=info:doi/10.1007%2Fs13318-018-0516-4&rft.externalDocID=10_1007_s13318_018_0516_4 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-7966&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-7966&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-7966&client=summon |